CA2153951A1 - Application de derives de 2h-1,2,4-benzothiadiazine-3(4h)-one-1,1-dioxyde comme antagonistes non competitifs du recepteur nmda - Google Patents

Application de derives de 2h-1,2,4-benzothiadiazine-3(4h)-one-1,1-dioxyde comme antagonistes non competitifs du recepteur nmda

Info

Publication number
CA2153951A1
CA2153951A1 CA002153951A CA2153951A CA2153951A1 CA 2153951 A1 CA2153951 A1 CA 2153951A1 CA 002153951 A CA002153951 A CA 002153951A CA 2153951 A CA2153951 A CA 2153951A CA 2153951 A1 CA2153951 A1 CA 2153951A1
Authority
CA
Canada
Prior art keywords
benzothiadiazine
dioxide
compounds
nmda receptor
salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002153951A
Other languages
English (en)
French (fr)
Inventor
Francois Audiau
Patrick Jimonet
Serge Mignani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2153951A1 publication Critical patent/CA2153951A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
CA002153951A 1993-03-03 1994-02-25 Application de derives de 2h-1,2,4-benzothiadiazine-3(4h)-one-1,1-dioxyde comme antagonistes non competitifs du recepteur nmda Abandoned CA2153951A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9302439A FR2702150B1 (fr) 1993-03-03 1993-03-03 Application de dérivés de 2H-1,2-4-benzothiadiazine-3(4H)-one-1,1-dioxyde comme antagonistes non compétitifs du récepteur NMDA.
FR93/02439 1993-03-03

Publications (1)

Publication Number Publication Date
CA2153951A1 true CA2153951A1 (fr) 1994-09-15

Family

ID=9444603

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002153951A Abandoned CA2153951A1 (fr) 1993-03-03 1994-02-25 Application de derives de 2h-1,2,4-benzothiadiazine-3(4h)-one-1,1-dioxyde comme antagonistes non competitifs du recepteur nmda

Country Status (10)

Country Link
EP (1) EP0687178A1 (xx)
JP (1) JPH08507303A (xx)
AU (1) AU6143694A (xx)
CA (1) CA2153951A1 (xx)
FR (1) FR2702150B1 (xx)
HU (1) HU9502572D0 (xx)
IL (1) IL108784A0 (xx)
NO (1) NO953387L (xx)
PL (1) PL310439A1 (xx)
WO (1) WO1994020109A1 (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
EP2117540A1 (en) 2007-03-01 2009-11-18 Probiodrug AG New use of glutaminyl cyclase inhibitors
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
SG178953A1 (en) 2009-09-11 2012-04-27 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
US9181233B2 (en) 2010-03-03 2015-11-10 Probiodrug Ag Inhibitors of glutaminyl cyclase
AU2011226074B2 (en) 2010-03-10 2015-01-22 Vivoryon Therapeutics N.V. Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB975925A (en) * 1961-02-21 1964-11-25 Scherico Ltd 3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxides
US4716161A (en) * 1984-04-17 1987-12-29 Mitsubishi Chemical Industries Limited Phenylpiperazine derivatives and their acid addition salts
FR2675801A1 (fr) * 1991-04-24 1992-10-30 Rhone Poulenc Rorer Sa Piperidines, leur preparation et les medicaments les contenant.
FR2690160A1 (fr) * 1992-04-15 1993-10-22 Rhone Poulenc Rorer Sa Application de dérivés d'acide 2H-1,2,4-benzothiadiazine-1,1-dioxyde-3-carboxylique à la préparation de médicaments, les produits nouveaux, leur préparation et les médicaments les contenant.
AU3957093A (en) * 1992-04-15 1993-11-18 Rhone-Poulenc Rorer S.A. 3,4-dihydro-2H-1,2,4-benzothiadiazine-1,1-dioxide-3-carboxyl ic acid derivatives, preparation thereof and drugs containing same

Also Published As

Publication number Publication date
PL310439A1 (en) 1995-12-11
FR2702150B1 (fr) 1995-04-07
EP0687178A1 (fr) 1995-12-20
WO1994020109A1 (fr) 1994-09-15
AU6143694A (en) 1994-09-26
JPH08507303A (ja) 1996-08-06
NO953387D0 (no) 1995-08-29
IL108784A0 (en) 1994-06-24
FR2702150A1 (fr) 1994-09-09
HU9502572D0 (en) 1995-11-28
NO953387L (no) 1995-08-29

Similar Documents

Publication Publication Date Title
EP0752988B1 (fr) DERIVES DE 5H-INDENO[1,2-b]PYRAZINE-2,3-DIONE ANTAGONISTES DES RECEPTEURS AMPA ET NMDA
CA2565293C (fr) Derives de tetrahydroisoquinolilsulfonamides, leur preparation et leur utilisation en therapeutique
EP0726900A1 (fr) 7H-IMIDAZO(1,2-a)PYRAZINE-8-ONE ANTAGONISTES DU RECEPTEUR NMDA
CA2152184A1 (fr) Derives de thiazolidine, leur preparation et les medicaments les contenant
EP0708778B1 (fr) Derives d'imidazo [1,2-a]pyrazine-4-one/utiles comme antagonistes des recepteurs ampa et nmda
CA2153951A1 (fr) Application de derives de 2h-1,2,4-benzothiadiazine-3(4h)-one-1,1-dioxyde comme antagonistes non competitifs du recepteur nmda
FR2707643A1 (fr) Dérivés d'imidazo[1,2-a]pyrazine-4-one, leur préparation et les médicaments les contenant.
FR2696466A1 (fr) Dérivés de 5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one, leur préparation et les médicaments les contenant.
EP0626367B1 (fr) Acide (7S)-7- (2R)-2-(3-chlorophényl)-2-hydroxyéthylamino -5,6,7,8-tétrahydronaphtalen-2-yloxy acétique, ses sels pharmaceutiquement acceptables, à action agoniste beta3 adrénergique, compositions pharmaceutiques et réactifs de laboratoire le contenant
FR2717811A1 (fr) Dérivés d'imidazo[1,2-a]pyrazine-4-one, leur préparation et les médicaments les contenant.
EP0375510B1 (fr) Dérivés d'imino-2 polyfluoroalcoxy-6 benzothiazole, leurs procédés de préparation et les médicaments les contenant
EP0788491B1 (fr) Derives de 6-polyfluoroalcoxy et 6-polyfluoroalkyle-2-aminobenzothiazole
WO1993021171A1 (fr) Application de derives d'acide 2h-1,2,4-benzothiadiazine-1,1-dioxyde-3-carboxylique a la preparation de medicaments antagonistes des recepteurs nmda/ampa, ainsi que produits nouveaux, leur preparation et les medicaments les contenant
EP1000067B1 (fr) Thiazolobenzoheterocycles, leur preparation et les medicaments les contenant
CA1227197A (fr) Derives de l'amino-5 dithiole-1,2 one-3 leur preparation et les compositions medicinales qui les contiennent
CA2074833A1 (fr) Derives d'(alkylthio-3 propyl)-3 benzothiazoline, leur preparation et les medicaments les contenant
FR2722786A1 (fr) Derives de 4-hydroxy-3-phenyl-indeno(1,2-b)pyridine-2(1h)- one, leur preparation et les medicaments les contenant
FR2649703A1 (fr) Derives d'imino-2 polyfluoroalcoxy-6 benzothiazole, leurs procedes de preparation et les medicaments les contenant
FR2649705A2 (fr) Medicaments a base de derives de la benzothiazolamine-2, nouveaux derives et leur preparation
FR2710062A1 (fr) Dérivés d'acide 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxyde-3-carboxylique, leur préparation et les médicaments les contenant.
FR2640624A1 (fr) Medicaments a base de derives de la benzothiazolamine-2, nouveaux derives et leur preparation
EP0580465A1 (fr) Nouvelle utilisation thérapeutique d'hétérocyclyl-pipérazines comme 5-HT3 agonistes et nouveaux dérivés
FR2643264A1 (fr) Trifluoromethoxy-5 benzimidazolamine-2, procede pour sa preparation et medicaments la contenant
FR2690159A1 (fr) Dérivés d'acide 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxyde-3-carboxylique, leur préparation et les médicaments les contenant.
FR2696457A1 (fr) Dérivés de 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxyde, leur préparation et les médicaments les contenant.

Legal Events

Date Code Title Description
FZDE Discontinued